BackDianthus Therapeutics Overview
Dianthus Therapeutics Inc

Dianthus Therapeutics Target Price

Where could DNTH trade next? Consensus target price: $130.

Get informed when a big investor buys or sells

+ Follow

Share Price

$112.11

Average Target Price

$131.3317.1% upside

6 analysts in the last 4 months

High: $158 | Low: $120

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-06H.C. Wainwright$15840.9% upsideOpen
2026-08-05Wedbush$1228.8% upsideOpen
2026-08-05Raymond JamesRyan Deschner$13116.8% upsideOpen
2026-06-10Jefferies$13217.7% upsideOpen
2026-05-11Evercore ISIGavin Clark-Gartner$1207% upsideOpen
2026-05-06Raymond James$12511.5% upsideOpen
2026-04-08Wolfe ResearchAndy Chen$9812.6% downsideOpen
2026-03-09UBSMaury Raycroft$9812.6% downsideOpen
2026-03-09JefferiesMaury Raycroft$9812.6% downsideOpen
2026-03-09Robert W. Baird$13217.7% upsideOpen
2026-03-09H.C. WainwrightSwayampakula Ramakanth$13016% upsideOpen
2026-03-09OppenheimerTrevor Allred$14529.3% upsideOpen
2026-03-09Stifel NicolausAlex Thompson$1207% upsideOpen
2026-03-09Truist Financial$1101.9% downsideOpen
2026-02-11Wedbush$5550.9% downsideOpen
2026-01-29UBS$12511.5% upsideOpen
2026-01-08Truist Financial$6343.8% downsideOpen
2025-11-06OppenheimerTrevor Allred$6244.7% downsideOpen
2025-10-14Truist FinancialDanielle Brill$5650% downsideOpen
2025-09-08GuggenheimYatin Suneja$10010.8% downsideOpen
2025-09-08JefferiesMaury Raycroft$5154.5% downsideOpen
2024-11-11OppenheimerLeland Gershell$5253.6% downsideOpen
2024-04-18Raymond JamesSteven Seedhouse$5154.5% downsideOpen

Dianthus Therapeutics (DNTH) FAQ

Dianthus Therapeutics's target price stands at $130. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $130 for DNTH implies 17.1% upside versus today's price ($112.11). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Dianthus Therapeutics's target price evolved across reporting periods, while the comparison chart places DNTH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Dianthus Therapeutics's reading of $130 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.